Updated Data Support Significant Clinical Benefit of Entrectinib in ROS1 Fusion+ NSCLC,

“This updated integrated analysis represents the largest prospective trial in patients with locally advanced or metastatic ROS1 fusion–positive NSCLC …, “This updated integrated analysis represents the largest prospective trial in patients with locally advanced or metastatic ROS1 fusion–positive NSCLC …, Read More

Scroll to Top